Colorectal cancer: Translation of biological pathways into molecular imaging

Nuclear Medicine Communications

Volumn 33, Issue 7, 2012, Pages 780-782

  Evangelista, Laura ^a   Marzola, Maria Cristina ^b   Chondrogiannis, Sotirios ^b   Al Nahhas, Adil ^c   Rubello, Domenico ^b  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b Santa Maria della Misericordia Hospital   (Italy)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; FLUORODEOXYGLUCOSE F 18; K RAS PROTEIN; VEMURAFENIB;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CHEMORADIOTHERAPY; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG EFFICACY; GENE MUTATION; HUMAN; LETTER; MOLECULAR IMAGING;

ANTINEOPLASTIC PROTOCOLS; BIOLOGICAL MARKERS; COLORECTAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; MOLECULAR IMAGING; MUTATION; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84862237177     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32835405ab     Document Type: Letter

References (16)

1. Capirci C, Rampin L, Rubello D, Galeotti F, Crepaldi G, Banti E, et al. Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy. Eur J Nucl Med Mol Imaging 2007; 34:1583-1593.
2. Capirci C, Rubello D, Pasini F, Galeotti F, Bianchini E, Del Favero G. The role of dual-time combined 18-fluorodeoxyglucose positron emission tomography and computed tomography in the staging and restaging workup of locally advanced rectal cancer, treated with preoperative chemoradiation therapy and radical surgery. Int J Radiat Oncol Biol Phys 2009; 74:1461-1493.
3. Grassetto G, Marzola MC, Minicozzi A, Al-Nahhas A, Rubello D. F-18 FDG PET/CT in rectal carcinoma: Where are we now? Clin Nucl Med 2011; 36:884-888.
4. Teng HW, Huang YC, Lin JK, Chen WS, Lin TC, Jiang JK, et al. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy. J Surg Oncol 2011; (in press). doi: 10.1002/jso.23063.
5. Kawada K, Nakamoto Y, Kawada M, Hida K, Matsumoto T, Murakami T, et al. Relationship between 18F-fluorodeoxyglucose accumulation and KRAS/BRAF mutations in colorectal cancer. Clin Cancer Res 2012; 18:1696-1703.
6. Bos Jl B. Ras oncogenes in human cancer: A review. Cancer Res 1989; 49:4682-4689.
7. Sakashita M, Aoyama N, Minami R, Maekawa S, Kuroda K, Shirasaka D, et al. Glut1 expression in T1 and T2 stage colorectal carcinomas: Its relationship to clinicopathological features. Eur J Cancer 2001; 37:204-209.
8. Osthus RC, Smith H, Kim S, Li Q, Reddy R, Mukherje M, et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem 2000; 275:21797-21800.
9. Mathupala SP, Ko YH, Pedersen PL, Hexokinase II. Cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 2006; 25:4777-4786.
10. Haberkorn U, Ziegler SI, Oberdorfer F, Trojan H, Haag D, Peschke P, et al. FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models. Nucl Med Biol 1994; 21:827-834.
11. Van Kouwen MC, Nagengast FM, Jansen JB, Oven WJ, Drenth JP. 2-(18F)- fluoro-2-deoxy-D-glucose positron emission tomography detects clinical relevant adenomas of the colon: A prospective study. J Clin Oncol 2005; 23:3713-3717.
12. Tatlidil R, Jadvar H, Badin JR, Conti PS. Incidental colonic fluorodeoxyglucose uptake: Correlation with colonoscopic and histopathologic findings. Radiology 2002; 224:783-787.
13. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE, et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418:934.
14. Volgestein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10:789-799.
15. McNeil C. K-Ras mutations are changing practice in advanced colorectal cancer. J Natl Cancer Inst 2008; 100:1667-1669.
16. Yang H, Higgins B, Kolinsky K, Packman K, Bradley WD, Lee RJ, et al. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res 2012; 72:779-789.